| 000 | 01757 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517114342.0 | ||
| 264 | 0 | _c20170526 | |
| 008 | 201705s 0 0 eng d | ||
| 022 | _a1432-0843 | ||
| 024 | 7 |
_a10.1007/s00280-016-3148-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEdelman, Martin J | |
| 245 | 0 | 0 |
_aPhase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors. _h[electronic resource] |
| 260 |
_bCancer chemotherapy and pharmacology _cNov 2016 |
||
| 300 |
_a959-967 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aArsenic _xblood |
| 650 | 0 | 4 |
_aArsenites _xadministration & dosage |
| 650 | 0 | 4 |
_aCisplatin _xadministration & dosage |
| 650 | 0 | 4 | _aEndpoint Determination |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLong QT Syndrome _xchemically induced |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aPlatinum _xblood |
| 650 | 0 | 4 |
_aSodium Compounds _xadministration & dosage |
| 650 | 0 | 4 |
_aTelomerase _xantagonists & inhibitors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aLapidus, Rena | |
| 700 | 1 | _aFeliciano, Josephine | |
| 700 | 1 | _aStyblo, Miroslav | |
| 700 | 1 | _aBeumer, Jan H | |
| 700 | 1 | _aLiu, Tao | |
| 700 | 1 | _aGobbru, Jogarao | |
| 773 | 0 |
_tCancer chemotherapy and pharmacology _gvol. 78 _gno. 5 _gp. 959-967 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00280-016-3148-x _zAvailable from publisher's website |
| 999 |
_c26411525 _d26411525 |
||